Unicoin defrauded investors through future crypto token scam, SEC alleges
The Securities and Exchange Commission (SEC) has charged cryptocurrency company Unicoin, three top executives, and its general counsel with defrauding investors of $110 million by selling them bogus “rights certificates” in a future cryptocurrency coin.
From February 2022 until May 20, Unicoin chief executive officer Alex Konanykhin, former president and board chair Silvina Moschini, and former chief investment officer and current board member Alex Dominguez offered certificates to the public that promised to convey rights to stock in a cryptocurrency asset, Unicoin tokens, that were not yet minted.
The executives, plus Unicoin general counsel Richard Devlin, claimed the crypto assets were backed by billions in real estate holdings and equity in startup companies.
Related articles
-
ArticleRole for compliance as FCA urges U.K. asset managers to take up tokenization tech
The U.K. Financial Conduct Authority (FCA) has opened a consultation on its plans to support “tokenization” – the digital representation of assets on distributed ledger technology (DLT). It is calling for firms to respond to the consultation before November 21. The financial regulator said in a press release on Oct. ...
-
Basic PageAtkins: SEC has too many vacancies following job losses under Trump
The Securities and Exchange Commission has too many vacancies following efforts by the Trump Administration to reduce the overall size of the federal government, SEC Chair Paul Atkins told Congress Tuesday.
-
News BriefCoinbase faces a leftover SEC probe as crypto enforcement loses steam
After dismissing its lawsuit against the crypto exchange Coinbase in March, a second investigation into the exchange by the Securities and Exchange Commission has surfaced, according to a report from the New York Times. This comes as a bit of a surprise after the Trump administration has been scaling down ...
More from Regulatory Policy
-
ArticlePharma sector boom puts pressure on compliance to counter financial crime
Regulation is a matter of life and death in the pharmaceutical industry. Rules to combat practices that can kill have been in force for decades, but tech developments are rapidly creating new risks and focusing lawmakers’ attention on areas where some compliance teams may lack experience.
-
News BriefCostco sues federal government over Trump-era tariffs, seeks refund rights
Wholesale retailer Costco would like a tariff refund from the U.S. government, if the U.S. Supreme Court rules that President Donald Trump overstepped his authority by imposing them.
-
PremiumU.K. data regulator pushes transparency on investigations
Plans to increase transparency around how the U.K.’s Information Commissioner investigates and fines companies should give businesses more clarity, but experts say the regulator still needs to explain how it will prioritize cases.